Jonathan Rubin - 02 Nov 2026 Form 4 Insider Report for Supernus, Inc. (INDV)

Reporting relationship: SVP, Chief Medical Officer
Issuer ticker: INDV
Reported as of: 02 Nov 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Nov 2026, 17:54:48 UTC
Prior SEC filing: 02 Nov 2026
Source filing: View source filing
Reporting owner signature: /s/ Timothy C. Dec, as attorney-in-fact

Filing notes and source

Key filing fact

Jonathan Rubin filed Form 4 for Supernus, Inc. (INDV) on 04 Nov 2026.

Key facts

This page summarizes Jonathan Rubin's Form 4 filing for Supernus, Inc. (INDV).
16 reported transactions and 15 derivative rows are listed below.
Accepted by SEC: 04 Nov 2026, 17:54.

Change

Previous filing in this sequence was filed on 02 Nov 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001836067 Primary reporting owner

Rubin Jonathan

Relationship: SVP, Chief Medical Officer
Address: C/O SUPERNUS, INC., 9715 KEY WEST AVENUE, ROCKVILLE
Signature: /s/ Timothy C. Dec, as attorney-in-fact
Signature date: 04 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INDV transaction

Common Stock

Other

Transaction value
Shares: +21,529
Change %
Price: $0.000000^*
Shares after: 21,529
Date: 02 Nov 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INDV transaction Derivative

Employee Stock Option (right to buy)

Other

Transaction value
Shares: +23,101
Change %
Price: $0.000000^*
Shares after: 23,101
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 23,101
Exercise price: $15.58
Footnotes: F2, F3

INDV transaction Derivative

Employee Stock Option (right to buy)

Other

Transaction value
Shares: +38,502
Change %
Price: $0.000000^*
Shares after: 38,502
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 38,502
Exercise price: $19.23
Footnotes: F2, F3

INDV transaction Derivative

Employee Stock Option (right to buy)

Other

Transaction value
Shares: +30,802
Change %
Price: $0.000000^*
Shares after: 30,802
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,802
Exercise price: $25.07
Footnotes: F2, F3

INDV transaction Derivative

Employee Stock Option (right to buy)

Other

Transaction value
Shares: +20,791
Change %
Price: $0.000000^*
Shares after: 20,791
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,791
Exercise price: $32.60
Footnotes: F2, F3

INDV transaction Derivative

Restricted Stock Units

Other

Transaction value
Shares: +1,925
Change %
Price: $0.000000^*
Shares after: 1,925
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,925
Exercise price: $0.000000
Footnotes: F2, F4

INDV transaction Derivative

Restricted Stock Units

Other

Transaction value
Shares: +3,850
Change %
Price: $0.000000^*
Shares after: 3,850
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,850
Exercise price: $0.000000
Footnotes: F2, F5

INDV transaction Derivative

Restricted Stock Units

Other

Transaction value
Shares: +5,197
Change %
Price: $0.000000^*
Shares after: 5,197
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,197
Exercise price: $0.000000
Footnotes: F2, F6

INDV transaction Derivative

Restricted Stock Units

Other

Transaction value
Shares: +4,620
Change %
Price: $0.000000^*
Shares after: 4,620
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,620
Exercise price: $0.000000
Footnotes: F2, F7

INDV transaction Derivative

Restricted Stock Units

Other

Transaction value
Shares: +107,807
Change %
Price: $0.000000^*
Shares after: 107,807
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 107,807
Exercise price: $0.000000
Footnotes: F2, F8

INDV transaction Derivative

Restricted Stock Units

Other

Transaction value
Shares: +2,695
Change %
Price: $0.000000^*
Shares after: 2,695
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,695
Exercise price: $0.000000
Footnotes: F2, F9

INDV transaction Derivative

Restricted Stock Units

Other

Transaction value
Shares: +1,155
Change %
Price: $0.000000^*
Shares after: 1,155
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,155
Exercise price: $0.000000
Footnotes: F2, F10

INDV transaction Derivative

Restricted Stock Units

Other

Transaction value
Shares: +1,540
Change %
Price: $0.000000^*
Shares after: 1,540
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,540
Exercise price: $0.000000
Footnotes: F2, F11

INDV transaction Derivative

Restricted Stock Units

Other

Transaction value
Shares: +1,886
Change %
Price: $0.000000^*
Shares after: 1,886
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,886
Exercise price: $0.000000
Footnotes: F2, F11

INDV transaction Derivative

Restricted Stock Units

Other

Transaction value
Shares: +1,886
Change %
Price: $0.000000^*
Shares after: 1,886
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,886
Exercise price: $0.000000
Footnotes: F2, F12

INDV transaction Derivative

Restricted Stock Units

Other

Transaction value
Shares: +1,617
Change %
Price: $0.000000^*
Shares after: 1,617
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,617
Exercise price: $0.000000
Footnotes: F2, F13

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 13 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/26, Artemis Merger Sub Inc. merged with and into Supernus Pharmaceuticals, with Supernus Pharmaceuticals surviving as a wholly-owned subsidiary of Indivior. At the effective time, each outstanding share of Supernus Pharmaceuticals common stock was cancelled and automatically converted into the right to receive 1.5401 shares of Indivior common stock. In connection with the merger, Indivior changed its name to "Supernus, Inc." The reporting person's shares of Supernus Pharmaceuticals common stock were disposed of, and the shares of Supernus, Inc. common stock received in exchange were acquired, pursuant to the merger. The reporting person received no cash consideration other than cash in lieu of a fractional share.

Footnote F2

Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards were converted into time-vesting restricted stock units.

Footnote F3

The option vests in four equal annual installments beginning on the specified date.

Footnote F4

These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.

Footnote F5

These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025.

Footnote F6

These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026.

Footnote F7

These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027.

Footnote F8

These restricted stock units ("RSUs") are settled in common stock upon vesting, which occurs in four installments. 50% of the RSUs vest upon the closing of the merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (the "Closing"). 15% of the RSUs vest upon the one-year anniversary of the Closing. 15% of the RSUs vest upon the two-year anniversary of the Closing. 20% of the RSUs vest upon the three-year anniversary of the Closing.

Footnote F9

These restricted stock units are settled in common stock upon vesting, which occurs on December 31, 2026.

Footnote F10

These restricted stock units are settled in common stock upon vesting, which occurs on December 31, 2027.

Footnote F11

These restricted stock units are settled in common stock upon vesting, which occurs on June 30, 2027.

Footnote F12

These restricted stock units are settled in common stock upon vesting, which occurs on June 30, 2029.

Footnote F13

These restricted stock units are settled in common stock upon vesting, which occurs on June 30, 2028.